Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2025

Michael O'Riordan

September 30, 2025

News Daily News

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

L.A. McKeown

July 15, 2025

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2023

Shelley Wood

July 31, 2023

News Daily News

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

L.A. McKeown

July 11, 2023

News Daily News

Top Endovascular News of 2022

L.A. McKeown

January 03, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News VIVA 2021

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

L.A. McKeown

October 07, 2021

News Opinion CV Team Dispatch

September 2021 News Roundup

L.A. McKeown

September 01, 2021

News Daily News

PAD Continues to Elude Clinicians, Despite Gains: AHA

L.A. McKeown

August 05, 2021

News Daily News

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

L.A. McKeown

April 22, 2021

News Daily News

No Paclitaxel Death Signal in VA Data Out to 3 Years

L.A. McKeown

February 11, 2021

The finding, from a study with a mean follow-up of 2-and-a-half years, bolsters support for trials and device use to continue.

News Daily News

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

L.A. McKeown

December 18, 2020

Advertisement

TCTMD’s Top 10 Most Popular Stories for September 2025

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

Top Endovascular News of 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

Top Endovascular News of 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

TCTMD’s Top 10 Most Popular Stories for July 2023

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

Top Endovascular News of 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

September 2021 News Roundup

PAD Continues to Elude Clinicians, Despite Gains: AHA

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

No Paclitaxel Death Signal in VA Data Out to 3 Years

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content